Healthcare Industry News: Cutaneous T-Cell Lymphoma
News Release - January 4, 2006
Biovest International Announces Addition to Senior Management TeamWORCESTER, Mass.--(HSMN NewsFeed)--Jan. 4, 2006--Biovest International, Inc. (OTCBB:BVTI ), a biopharmaceutical company focused on the development of patient specific immunotherapeutics and automated cell culture instrumentation announced that Donna Jordan has joined the company as Vice President of Quality Control and Quality Assurance. Most recently, Ms. Jordan was Director of Quality Systems at RenaMed Biologics in Lincoln, RI where she was responsible for the Quality Assurance, Quality Control and Validation departments in support of the initiation of in-house manufacturing of a combination product currently in Phase 2 clinical trials. Her previous positions include Director of Quality Assurance at VI Technologies in Watertown, Mass. and Director of Quality Systems at Q-One Biotech in Worcester, Mass. From 1990-2000 Ms Jordan held positions of increasing responsibility at Seragen in Hopkinton, Mass., rising to the position of Manager, Quality Assurance. At Seragen she played a key role in bringing a biologic product (Ontak, for Cutaneous T-Cell Lymphoma) from development through commercialization.
Carl M. Cohen, Ph.D., Chief Operating Officer of Biovest commented, "We are pleased that Donna has joined Biovest. She brings a wealth of highly relevant experience to our company. As we begin to ramp up our manufacturing capacity and significantly expand our Quality Control, Quality Assurance and Quality Engineering groups, Donna's demonstrated skills at creating and managing a world-class quality organization will be essential to our success. Donna joins a senior management team that is focused on the evaluation and commercial launch of BiovaxID(TM) for the treatment of indolent follicular non-Hodgkin's lymphoma."
About Biovest International
Biovest International, Inc. (OTCBB:BVTI ) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI ). Biovest has a foundation in the manufacture of biologics for research and for clinical trials. In addition, Biovest develops, manufactures, and markets patented cell culture systems, including the AutovaxID(TM), which is being developed as an automated vaccine manufacturing instrument. Biovest's therapy for follicular non-Hodgkin's lymphoma is currently in a Phase 3 pivotal clinical trial at over 20 major centers in the U.S. being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. For further information, please visit Biovest's website: http://www.biovest.com.
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about BiovaxID and AutovaxID and any other statements relating to Biovest's products, product candidates, and product development programs. Such statement may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Biovest's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of Biovest's clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in Biovest's filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Source: Biovest International
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.